Navigation Links
Johns Hopkins researchers discover how some breast cancers alter their sensitivity to estrogen
Date:7/27/2011

Using human breast cancer cells and the protein that causes fireflies to glow, a Johns Hopkins team has shed light on why some breast cancer cells become resistant to the anticancer effects of the drug tamoxifen. The key is a discovery of two genetic "dimmer switches" that apparently control how a breast cancer gene responds to the female hormone estrogen.

In a report published online July 7 by Human Molecular Genetics, the scientists show how a gene known as RET in breast cancer cells responds to estrogen by dialing up the manufacture of a signaling protein that instructs cells to divide and causes tumors to become aggressive through the escape from estrogen dependence.

Scientists have long known that breast cancers are either estrogen-receptor positive or estrogen-receptor negative. The positive subset, generally associated with better outcomes for patients, is sensitive to the drug tamoxifen, which blunts aggressive tumor growth through estrogen receptor inhibition, according to Zachary E. Stine, the research team's lead author and a postdoctoral fellow working in the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.

Used for decades to prevent and treat breast tumors that kill about 40,000 women a year, tamoxifen works on some types of breast cancers by interfering with the activity of estrogen. However, resistance to the drug frequently develops over time, and previous experiments by other laboratories have shown that RET plays some role in either altering resistance or maintaining it.

Thus, the Hopkins scientists focused on RET, searching for pieces of DNA in the vicinity of that gene that had the potential, when combined with estrogen, to act as switches controlling the amount of protein product RET manufactures.

After identifying 10 sites in the RET locus that bind with estrogen receptor alpha, the investigators cloned the DNA sequences in those areas, then attached to each a piece of genetic material responsible for producing luciferase, an enzyme that causes the luminescent glow of a firefly. This lab product was then put inside human breast cancer cells in a dish and exposed to estrogen. Two of the 10 sequences lit up much more brightly than the others, revealing increased activity by the RET gene in response to estrogen.

"Those two sequences clearly are genetic hubs for the dialing up and dialing down of RET activity in response to estrogen," says Andrew McCallion, Ph.D., an associate professor in the McKusick-Nathans Institute of Genetic Medicine, and corresponding author on the study.

In a second experiment, the team used the cloned sequence and luciferase concoction, inserted it into a breast cancer gene, and this time added retinoic acid instead of estrogen. Retinoic acid is well known to slow cancer cell growth. The scientists showed that one of the two sequences previously shown to be estrogen responsive also responded to retinoic acid and increased RET activity.

The investigators also found that when they put estrogen and retinoic acid together in breast cancer cells in culture, the increased activity of RET was much greater compared to either estrogen or retinoic acid alone.

Because it appears that increased RET activity is linked to more aggressive and tamoxifen-resistant types of breast cancers, the discovery is potentially important for making decisions about tamoxifen use, McCallion says. Understanding the genetics of these proteins also has the potential to guide the search for new therapeutic targets in breast cancer. With the new information, he says, steps might be taken to "resensitize" tumors that become tamoxifin- insensitive by manipulating the regulators of RET and, therefore, its protein products.


'/>"/>

Contact: Maryalice Yakutchik
myakutc1@jhmi.edu
443-287-2251
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Jimmy Johnson Will Step Into Role as Honorary Crew Chief for ExtenZe Racing at Daytona
2. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
3. Longtime Quality Assurance Executive Randy Johnson Joins White Pine Systems as Vice President of Product Services
4. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
5. AADR awards the 2010 Jack Hein Public Service Award to David C. Johnsen
6. Johnson & Johnson to Participate in RBC Capital Markets Health Care Conference
7. Robert Wood Johnson Foundation Launches New Scholars, Fellows & Leadership Programs Web Site
8. Johns Hopkins Launches “Energy Policy and Climate” Master's Degree
9. SC Johnson and Bill & Melinda Gates Foundation Unite to Combat Malaria
10. Johns Hopkins Health System Acquires Imorgon Ultrasound PACS Product
11. Cancer research award to Johns Hopkins basic scientist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a ... Migraine Relief with the 2017 Women’s Choice Award. The identification by women of an ... out of 4 migraine sufferers are women. In a survey taken by the Women’s ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... good health is as simple as eating healthy foods. But this well-known piece ... fat, making insulin, or breaking apart carbohydrates—depends not only on properties of the ...
(Date:8/22/2017)... ... 22, 2017 , ... Western North Carolina’s only certified fellow ... aesthetics conference for medical professionals about the positive impact Juliet™ feminine rejuvenation ... practice. , Dr. George K. Ibrahim shared the results of his ...
(Date:8/22/2017)... ... August 22, 2017 , ... Pivot ... addition of Zack Tisch as the firm’s new Consulting Services Executive. Mr. Tisch ... firm’s national accounts, from assisting clients with initial vendor selection and pre-implementation planning ...
(Date:8/22/2017)... ... August 22, 2017 , ... Each of the past six years, Lightning Labels has sent ... these labels and stickers, demonstrating the variety and creativity of their designs. Submissions this year ... came in. Now, it's time to announce the winners of the sixth annual Photo Contest, ...
Breaking Medicine News(10 mins):
(Date:8/18/2017)... today announced the awarding of a $688K National Institutes of Health (NIH) grant. The award ... Small Business Innovation Research (SBIR)?Fast-track grant under award number R44NS095585 ... (NINDS).?  ... Nortis ParVivo Chip used for 3D Organs-on-Chip Applications ... The neurotherapeutics sector is among ...
(Date:8/17/2017)... 17, 2017 MJAC2017 , the premier cannabis ... Media, today reveals its leading lineup. MJAC2017 ... global cannabis innovator specializing in the development of pharmaceutical and ... MassRoots, Rambridge™ and The Green Organic Dutchman are gold sponsors ... Vapes™ as silver sponsors. ...
(Date:8/17/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading ... big data solutions, announced today that it has ... investors for the sale of shares of the ... newly designated Series B Convertible Preferred Stock in ... conduct a closing with respect to the offerings ...
Breaking Medicine Technology: